FrancophonIA/ELRC3.0 huggingface dataset:
English: Patients should be treated, if appropriate, after initiating Erleada for these conditions according to established treatment guidelines.
Slovenian: Če je primerno, se po uvedbi zdravila Erleada, te bolezni zdravi po ustaljenih smernicah.
English: 30-day carton
Slovenian: Škatla s 30-dnevnim pakiranjem
English: Manufacturer Janssen Cilag SpA Via C. Janssen Borgo San Michele Latina 04100, Italy
Slovenian: Izdelovalec Janssen Cilag S.P.A Via C. Janssen, Borgo San Michele, Latina 04100, Italija
English: Skin and subcutaneous tissue disorders very common: skin rash** common: pruritus
Slovenian: Bolezni kože in podkožja zelo pogosti: kožni izpuščaj** pogosti: srbenje
English: It is unknown whether apalutamide/metabolites are excreted in human milk.
Slovenian: Ni znano, ali se apalutamid oziroma njegovi presnovki izločajo v materino mleko.
English: For the active moieties (sum of apalutamide plus the potency adjusted active metabolite), Cmax decreased by 21% while AUC increased by 45%.
Slovenian: Pri aktivnih frakcijah (vsota apalutamida in aktivnega presnovka s prilagajanjem na potentnost) se je Cmax zmanjšala za 21% in AUC povečala za 45%.
English: Substitution for these medicinal products is recommended when possible or evaluation for loss of efficacy should be performed if the medicinal product is continued.
Slovenian: Če je le mogoče, je ta zdravila priporočljivo zamenjati z nadomestnimi, oziroma v primeru nadaljevanja zdravljenja z istim zdravilom oceniti obseg zmanjšanja učinka.
English: Do not use this medicine after the expiry date which is stated on the container (blister foils, inner wallet, outer wallet, bottle, and carton) after EXP.
Slovenian: Tega zdravila ne smete uporabljati po datumu izteka roka uporabnosti, ki je naveden na vsebniku (na foliji, notranji zgibanki, zunanji zgibanki, plastenki in škatli) poleg oznake EXP. Rok uporabnosti zdravila se izteče na zadnji dan navedenega meseca.
English: Based on the drug-drug interaction study results with strong CYP3A4 inhibitor or strong CYP2C8 inhibitor, CYP3A4 or CYP2C8 inducers are not expected to have clinically relevant effects on the pharmacokinetics of apalutamide and the active moieties therefore no dose adjustment is necessary when Erleada is co-administered with inducers of CYP3A4 or CYP2C8.
Slovenian: Na osnovi rezultatov študij medsebojnega delovanja z močnimi zaviralci CYP3A4 ali močnimi zaviralci CYP2C8, ni pričakovati, da bi induktorji CYP3A4 ali CYP2C8 klinično pomembno vplivali na farmakokinetiko apalutamida in aktivnih frakcij, zato pri sočasni uporabi zdravila Erleada z induktorji CYP3A4 ali CYP2C8, prilagoditev odmerka ni potrebna.
English: Nervous system disorders uncommon: seizure (see section 4.4)
Slovenian: Bolezni živčevja občasni: konvulzije (glejte poglavje 4.4)
English: INFORMATION IN BRAILLE Erleada 60 mg
Slovenian: Erleada 60 mg
English: Following a single oral 240 mg dose of apalutamide, the geometric mean ratio (GMR) for AUC and Cmax for apalutamide in subjects with mild impairment was 95% and 102%, respectively, and the GMR for AUC and Cmax of apalutamide in subjects with moderate impairment was 113% and 104%, respectively, compared to healthy control subjects.
Slovenian: Po enkratnem peroralnem odmerku 240 mg apalutamida sta bili geometrični povprečji razmerja za AUC in Cmax apalutamida med bolniki z blago okvaro in zdravimi kontrolnimi preiskovanci 95% in 102%, med bolniki z zmerno okvaro jeter in zdravimi kontrolnimi preiskovanci pa 113% in 104%.
English: In humans, Erleada is a strong inducer of CYP3A4 and CYP2C19, and a weak inducer of CYP2C9.
Slovenian: Pri človeku je zdravilo Erleada močan induktor CYP3A4 in CYP2C19 ter šibak induktor CYP2C9.
English: Apalutamide and N-desmethyl apalutamide do not affect CYP1A2 and CYP2D6 at therapeutically relevant concentrations.
Slovenian: Apalutamid in N-desmetil apalutamid pa v terapevtsko pomembnih koncentracijah ne vplivata na CYP1A2 in CYP2D6.
English: Medicinal products which prolong the QT interval Since androgen deprivation treatment may prolong the QT interval, the concomitant use of Erleada with medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de pointes such as class IA (e.g., quinidine, disopyramide) or class III (e.g., amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics (e.g. haloperidol), etc. should be carefully evaluated (see section 4.4).
Slovenian: Ker lahko zdravljenje z odtegnitvijo androgenov podaljša interval QT, je potrebna skrbna presoja glede sočasne uporabe zdravila Erleada z zdravili, za katera je ugotovljeno, da podaljšujejo interval QT, oziroma z zdravili, ki lahko izzovejo Torsades de pointes, kot so antiaritmiki razreda IA (npr. kinidin, dizopiramid) ali razreda III (npr. amjodaron, sotalol, dofetilid, ibutilid), metadon, moksifloksacin, antipsihotiki (npr. haloperidol) in podobna zdravila (glejte poglavje 4.4).
English: White opaque high-density polyethylene (HDPE) bottle with a polypropylene (PP) child-resistant closure.
Slovenian: Bela neprozorna plastenka iz polietilena velike gostote (HDPE) z za otroke varno polipropilensko (PP) zaporko.
English: In patients not receiving thyroid replacement therapy, hypothyroidism occurred in 5.7% of patients treated with Erleada and in 0.8% of patients treated with placebo.
Slovenian: Med bolniki, ki niso prejemali nadomestnih ščitničnih hormonov, je do hipotiroidizma prišlo pri 5,7% bolnikov, ki so prejemali zdravilo Erleada, in pri 0,8% bolnikov, ki so prejemali placebo.
English: Concomitant use of Erleada with medicinal products that are substrates of P-gp (e.g., colchicine, dabigatran etexilate, digoxin), BCRP or OATP1B1 (e.g., lapatinib, methotrexate, rosuvastatin, repaglinide) can result in lower exposure of these medicinal products.
Slovenian: Sočasno dajanje zdravila Erleada z zdravili, ki so substrati P-gp (kot so kolhicin, dabigatran eteksilat, digoksin), ali substrati BCRP ali OATP1B1 (kot so lapatinib, metotreksat, rosuvastatin in repaglinid) lahko povzroči zmanjšanje izpostavljenosti tem zdravilom.
English: N-desmethyl apalutamide is characterised by a flat concentration-time profile at steady-state with a mean peak-to-trough ratio of 1.27.
Slovenian: N-desmetil apalutamid ima v stanju dinamičnega ravnovesja precej enakomeren profil časovnega poteka koncentracije s povprečno vrednostjo razmerja med najvišjo in najnižjo koncentracijo 1,27.
English: The tablets are supplied in a plastic bottle with a child-resistant closure.
Slovenian: Tablete so na voljo v plastenki z za otroke varno zaporko.
English: Concomitant use of Erleada with medicinal products that are primarily metabolised by CYP3A4 (e.g., darunavir, felodipine, midazolam, simvastatin), CYP2C19 (e.g., diazepam, omeprazole), or CYP2C9 (e.g., warfarin, phenytoin) can result in lower exposure to these medicinal products.
Slovenian: Sočasna uporaba zdravila Erleada z zdravili, ki se primarno presnavljajo s CYP3A4 (kot so darunavir, felodipin, midazolam in simvastatin), s CYP2C19 (kot sta diazepam in omeprazol) ali s CYP2C9 (kot sta varfarin in fenitoin), lahko povzroči zmanjšanje izpostavljenosti tem zdravilom.
English: A total of 1207 subjects with NM-CRPC were randomised 2:1 to receive either apalutamide orally at a dose of 240 mg once daily in combination with androgen deprivation therapy (ADT) (medical castration or prior surgical castration) or placebo with ADT in a multicenter, double-blind, clinical study (Study ARN-509-003).
Slovenian: V multicentrični, dvojno slepi klinični študiji (študiji ARN-509-003) so skupno 1207 preiskovancev z NM-CRPC, randomizirali v razmerju 2:1 tako, da so prejemali bodisi 240 mg apalutamida peroralno enkrat na dan v kombinaciji z zdravljenjem z deprivacijo androgenov (ADT - androgen deprivation therapy) (medikamentna kastracija ali predhodna kirurška kastracija) ali placebo skupaj z ADT.
English: Patients should be evaluated for fractures and fall risk before starting Erleada and should continue to be monitored and managed for fractures according to established treatment guidelines and use of bone-targeted agents should be considered.
Slovenian: Pred uvedbo zdravljenja z zdravilom Erleada je treba pri bolnikih oceniti tveganje za zlome in padce, bolnike s tveganjem za zlome pa spremljati po ustaljenih smernicah in premisliti o uporabi učinkovin, ki delujejo na kosti.
English: humerus fracture, thoracic vertebral fracture, upper limb fracture, fractured sacrum, hand fracture, pubis fracture, acetabulum fracture, ankle fracture, compression fracture, costal cartilage fracture, facial bones fracture, lower limb fracture, osteoporotic fracture, wrist fracture, avulsion fracture, fibula fracture, fractured coccyx, pelvic fracture, radius fracture, sternal fracture, stress fracture, traumatic fracture, cervical vertebral fracture, femoral neck fracture, tibia fracture.
Slovenian: Vključuje zlom rebra, zlom ledvenega vretenca, kompresijski zlom vretenca, zlom hrbtenice, zlom stopala, zlom kolka, zlom nadlahtnice, zlom prsnega vretenca, zlom zgornje okončine, zlom križnice, zlom roke, zlom sramnice, zlom acetabuluma, zlom gležnja, kompresijski zlom, zlom hrustančnega dela rebra, zlom obraznih kosti, zlom spodnje okončine, osteoporotični zlom, zlom zapestja, avulzijski zlom, zlom mečnice, zlom trtice, zlom medenice, zlom koželjnice, zlom prsnice, stresni zlom, travmatski zlom, zlom vratnega vretenca, zlom vratu stegnenice, zlom golenice.
English: Based on in vitro data, inhibition of organic cation transporter 2 (OCT2), organic anion transporter 3 (OAT3) and multidrug and toxin extrusions (MATEs) by apalutamide and its N-desmethyl metabolite cannot be excluded.
Slovenian: Na osnovi podatkov in vitro ni mogoče izključiti možnosti, da apalutamid in njegov N-desmetil presnovek zavirata prenašalec organskih kationov 2 (OCT2 - organic cation transporter 2), prenašalec organskih anionov 3 (OAT3 - organic anion transporter 3) in protein za ekstruzijo več zdravil in toksinov (MATE - multidrug and toxin extrusion protein).
English: Skin rash recurred in approximately half of patients who were re-challenged.
Slovenian: Do ponovitve kožnega izpuščaja je prišlo pri približno polovici bolnikov, ki so jim po prekinitvi uporabe zdravilo ponovno uvedli.
English: Apalutamide and N-desmethyl apalutamide are further metabolised to form the inactive carboxylic acid metabolite by carboxylesterase.
Slovenian: Apalutamid in N-desmetil apalutamid se še naprej presnavljata, pri čemer s pomočjo karboksilesteraze nastaja neaktivni karboksilnokislinski presnovek.
English: Falls and fractures occurred in patients receiving Erleada (see section 4.8).
Slovenian: Pri bolnikih, ki so prejemali zdravilo Erleada je prišlo do padcev in zlomov (glejte poglavje 4.8).
English: Adverse reactions of skin rash were reported for 24% of patients treated with Erleada.
Slovenian: O kožnih izpuščajih so poročali pri 24% bolnikov, ki so prejemali zdravilo Erleada.
English: Each film-coated tablet contains 60 mg of apalutamide.
Slovenian: Ena filmsko obložena tableta vsebuje 60 mg apalutamida.
English: Seizure occurred in 0.2% of patients receiving Erleada in clinical studies.
Slovenian: V kliničnih študijah je do konvulzij prišlo pri 0,2% bolnikov, ki so prejemali zdravilo Erleada.
English: It is metabolised primarily by CYP2C8 and CYP3A4 to form N-desmethyl apalutamide.
Slovenian: Presnavlja se predvsem s CYP2C8 in CYP3A4, pri čemer nastaja N-desmetil apalutamid.
English: • You can take Erleada with food or between meals.
Slovenian: • Zdravilo Erleada lahko jemljete skupaj s hrano ali brez nje.
English: In a drug-drug interaction study using a cocktail approach, co-administration of Erleada with single oral doses of sensitive CYP substrates resulted in a 92% decrease in the AUC of midazolam (CYP3A4 substrate), 85% decrease in the AUC of omeprazole (CYP2C19 substrate), and 46% decrease in the AUC of S-warfarin (CYP2C9 substrate).
Slovenian: V študiji interakcij z uporabo mešanice substratov je sočasno odmerjanje zdravila Erleada z enkratnimi peroralnimi odmerki občutljivih substratov CYP povzročilo 92-odstotno zmanjšanje AUC midazolama (substrata CYP3A4), 85% zmanjšanje AUC omeprazola (substrata CYP2C19) in 46% zmanjšanje AUC S-varfarina (substrata CYP2C9).
English: If you take more than you should, stop taking Erleada and contact your doctor.
Slovenian: Če ste vzeli večji odmerek zdravila Erleada, kot bi smeli Če ste vzeli več zdravila, kot bi smeli, prenehajte jemati zdravilo Erleada in se posvetujte z zdravnikom.
English: There is no clinical experience in re-administering Erleada to patients who experienced a seizure.
Slovenian: Kliničnih izkušenj s ponovno uvedbo zdravila Erleada bolnikom, pri katerih je prišlo do konvulzij, ni.
English: The effects of CYP3A4 or CYP2C8 inducers on the pharmacokinetics of apalutamide have not been evaluated in vivo.
Slovenian: Vpliva induktorjev CYP3A4 in CYP2C8 na farmakokinetiko apalutamida niso ocenjevali v raziskavah in vivo.
English: Iron oxide black (E172) Iron oxide yellow (E172) Macrogol
Slovenian: Filmska obloga črni železov oksid (E172) rumeni železov oksid (E172) makrogol polivinilalkohol (delno hidroliziran) smukec titanov dioksid (E171)
English: There were no statistically significant differences observed in the change from baseline analysis of the Functional Assessment of Cancer Therapy-Prostate (FACT-P) for the total score or any of the subscales between subjects on Erleada added to ADT versus placebo with ADT.
Slovenian: Pri analizi spremembe od izhodišča niso opažali statistično značilne razlike med skupinama preiskovancev, ki so prejeli zdravilo Erleada skupaj z ADT oziroma placebo skupaj z ADT niti pri celotni oceni niti pri ocenah pri posameznih podlestvicah funkcionalne ocene zdravljenja bolnikov z rakom prostate (FACT-P - Functional Assessment of Cancer Therapy-Prostate).
English: Concomitant administration of Erleada with medicinal products that are substrates of UGT (e.g., levothyroxine, valproic acid) can result in lower exposure to these medicinal products.
Slovenian: Sočasna uporaba zdravila Erleada z zdravili, ki so substrati UDP-glukuronil transferaze (kot so levotiroksin, valprojska kislina), lahko povzroči zmanjšanje izpostavljenosti tem zdravilom.
English: If a seizure develops during treatment with Erleada, treatment should be discontinued permanently.
Slovenian: Če pri bolniku pride do konvulzij med zdravljenjem z zdravilom Erleada, mu je treba zdravilo dokončno ukiniti.
English: 4.7 Effects on ability to drive and use machines Erleada has no or negligible influence on the ability to drive and use machines.
Slovenian: Zdravilo Erleada nima vpliva ali ima zanemarljiv vpliv na sposobnost vožnje in upravljanja strojev.
English: PVC-PCTFE foil blister with an aluminum push-through foil sealed inside a wallet pack.
Slovenian: Pretisni omot iz polivinilklorida/polikloro-trifluoroetilena (PVC/PCTFE) z aluminijasto pretisno folijo, zaprt v škatlo v obliki zgibanke.
English: Clădirea S-Park, Corp B3-B4, Etaj 3 013714 Bucureşti, ROMÂNIA Tel: +40 21 207 18 00
Slovenian: Clădirea S-Park, Corp B3-B4, Etaj 3 013714 Bucureşti.
English: Apalutamide is an orally administered, selective Androgen Receptor (AR) inhibitor that binds directly to the ligand-binding domain of the AR.
Slovenian: Apalutamid s peroralnim odmerjanjem je selektivni zaviralec androgenskih receptorjev, ki se na androgenskih receptorjih veže neposredno na domeno za vezavo ligandov.
English: In vitro, apalutamide and its N-desmethyl metabolite are substrates for P-gp.
Slovenian: In vitro sta apalutamid in njegov N-desmetil presnovek substrata P-glikoproteina.
English: Biotransformation Following single oral administration of
Slovenian: Biotransformacija Po aplikaciji enkratnega peroralnega odmerka 240 mg s
English: The contribution of CYP2C8 and CYP3A4 in the metabolism of apalutamide is estimated to be 58% and 13% following single dose but the level of contribution is expected to change at steady-state due to induction of CYP3A4 by apalutamide after repeat dose.
Slovenian: Ocenjeni delež CYP2C8 pri presnovi apalutamida po dajanju enkratnega odmerka je 58%, delež CYP3A4 pa 13%, vendar se v stanju dinamičnega ravnovesja ta deleža spremenita zaradi indukcije apalutamida po večkratnem odmerjanju s CYP3A4.
English: Mild or moderate inhibitors of CYP3A4 are not expected to affect the exposure of apalutamide.
Slovenian: Pri uporabi blagih ali zmernih zaviralcev CYP3A4 ni pričakovati vpliva na izpostavljenost apalutamidu.
English: In a drug-drug interaction study, the Cmax of apalutamide decreased by 21% while AUC increased by 68% following co-administration of apalutamide 240 mg single dose with gemfibrozil (strong CYP2C8 inhibitor).
Slovenian: V študiji medsebojnega delovanja med učinkovinama se je Cmax apalutamida zmanjšala za 21%, njegova AUC pa se je povečala za 68% po sočasnem odmerjanju enkratnega, 240 mg odmerka apalutamida in gemfibrozila (močnega zaviralca CYP2C8).
English: • Take this medicine by mouth.
Slovenian: • Zdravilo morate zaužiti.
English: A dedicated hepatic impairment study compared the systemic exposure of apalutamide and N- desmethyl apalutamide in subjects with baseline mild hepatic impairment (N=8, Child-Pugh Class A, mean score = 5.3) or moderate hepatic impairment (N=8, Child-Pugh Class B, mean score = 7.6)
Slovenian: V posebni študiji pri okvari jeter so primerjali sistemsko izpostavljenost apalutamidu in N- desmetil apalutamidu pri preiskovancih, ki so imeli ob izhodišču blago okvaro jeter, (N=8, Child-Pugh razreda A, povprečna ocena = 5,3) ali zmerno okvaro jeter (N=8, Child-Pugh razreda B, povprečna ocena = 7,6) z vrednostmi pri zdravih kontrolah z normalno jetrno funkcijo (N=8).
English: Day
Slovenian: dan
English: No dose adjustment is necessary for patients with baseline mild or moderate hepatic impairment (Child-Pugh Class A and B, respectively).
Slovenian: Bolnikom z izhodiščno blago ali zmerno okvaro jeter (Child-Pugh razreda A oziroma B) odmerka ni treba prilagajati.
English: The CL/F of apalutamide is 1.3 L/h after single dosing and increases to 2.0 L/h at steady-state after once-daily dosing.
Slovenian: Navidezni očistek (CL/F) apalutamida po dajanju enkratnega odmerka je 1,3 l/h, v stanju dinamičnega ravnovesja po odmerjanju enkrat dnevno pa se poveča na 2,0 l/h.
English: Medical castration with gonadotropin releasing hormone analogue (GnRHa) should be continued during treatment in patients not surgically castrated.
Slovenian: Med zdravljenjem je treba pri bolnikih, ki niso bili kirurško kastrirani, nadaljevati medicinsko kastracijo z analogom gonadoliberina (GnRHa - gonadotropin-releasing hormone analogue).
English: Thyroid replacement therapy, when clinically indicated, should be initiated or dose-adjusted (see section 4.5).
Slovenian: Bolnikom je treba uvesti nadomestno ščitnično zdravljenje, kadar je klinično indicirano, ali pa prilagoditi odmerek zdravila (glejte poglavje 4.5).
English: Seventy-three percent (73%) of subjects received prior treatment with a first generation anti-androgen; 69% of subjects received bicalutamide and 10% of subjects received flutamide.
Slovenian: Pri petnajstih odstotkih (15%) preiskovancev je bila ob vstopu v študijo velikost pelvičnih bezgavk < 2 cm. Triinsedemdeset odstotkov (73%) preiskovancev je predhodno prejemalo zdravljenje z antiandrogeni prve generacije, 69% preiskovancev je prejemalo bikalutamid in 10% flutamid.
English: Colloidal anhydrous silica Croscarmellose sodium Hypromellose acetate succinate Magnesium stearate Microcrystalline cellulose Microcrystalline cellulose (silicified)
Slovenian: Jedro tablete brezvodni koloidni silicijev dioksid premreženi natrijev karmelozat hipromeloza acetat sukcinat magnezijev stearat mikrokristalna celuloza mikrokristalna celuloza (silicificirana)
English: A dedicated renal impairment study for apalutamide has not been conducted.
Slovenian: Posebnih študij apalutamida pri okvari ledvic niso izvedli.
English: Slightly yellowish to greyish green, oblong-shaped, film-coated tablets (16.7 mm long x 8.7 mm wide), debossed with “AR 60” on one side.
Slovenian: Rahlo rumenkaste do sivozelene podolgovate (16,7 mm dolge in 8,7 mm široke) filmsko obložene tablete, ki imajo na eni strani vtisnjeno oznako “AR 60”.
English: In a fertility study in male rats, a decrease in sperm concentration and motility, copulation and fertility rates (upon pairing with untreated females) along with reduced weights of the secondary sex glands and epididymis were observed following 4 weeks of dosing at doses corresponding to exposures approximately equal to the human exposure based on AUC.
Slovenian: V študiji plodnosti pri samcih podgan so po 4 tednih uporabe odmerkov, ki so glede na AUC ustrezali približno tolikšni izpostavljenosti, kot jo dosegamo pri ljudeh, opažali zmanjšano koncentracijo in gibljivost semenčic, zmanjšani stopnji kopulacije in plodnosti (po parjenju z nezdravljenimi samicami) ter zmanjšano maso sekundarnih spolnih žlez in epididimisa.
English: At steady-state, the mean (CV%) Cmax and AUC values for the major active metabolite, N-desmethyl apalutamide, were 5.9 µg/mL (18%) and 124 µg.h/mL (19%), respectively.
Slovenian: V stanju dinamičnega ravnovesja je bila povprečna vrednost Cmax poglavitnega aktivnega presnovka N-desmetil apalutamida 5,9 µg/ml (s koeficientom variacije 18%), njegova povprečna AUC pa 124 µg.h/ml (s koeficientom variacije 19%).
English: P-gp, BCRP or OATP1B1 are co-administered with Erleada, evaluation for loss of efficacy of the substrate should be performed and dose adjustment of the substrate may be required to maintain optimal plasma concentrations.
Slovenian: Če je substrate prenašalcev P-gp, BCRP ali OATP1B1 treba uporabljati sočasno z zdravilom Erleada, je potrebna ocena obsega zmanjšanja učinka ter za zagotovitev optimalnih plazemskih koncentracij morda prilagoditi odmerek substrata .
English: At steady-state, mean (CV%) Cmax and AUC values for apalutamide were 6 µg/mL (28%) and 100 µg.h/mL (32%), respectively.
Slovenian: V stanju dinamičnega ravnovesja, je bila povprečna vrednost Cmax apalutamida 6 µg/ml (s koeficientom variacije 28%), povprečna AUC pa 100 µg.h/ml (s koeficientom variacije 32%).
English: Each bottle contains 120 tablets and a total of 6 g of desiccant.
Slovenian: Ena plastenka vsebuje 120 tablet in skupno 6 g sušilnega sredstva.
English: Hypothyroidism occurred in 28% of patients already receiving thyroid replacement therapy in the Erleada arm and in 5.9% of patients in the placebo arm.
Slovenian: Med bolniki, ki so že prejemali nadomestne ščitnične hormone, je do hipotiroidizma prišlo pri 28% bolnikov v skupini z zdravilom Erleada in pri 5,9% bolnikov v skupini s placebom.
English: Each bottle contains 120 film-coated tablets and a total of 6 g of silica gel desiccant.
Slovenian: Ena plastenka vsebuje 120 filmsko obloženih tablet in skupno 6 g sušilnega sredstva iz silikagela.
English: Do not swallow or discard the desiccant.
Slovenian: Sušilnega sredstva ne zaužijte ali zavrzite.
English: The median survival for the apalutamide arm was not reached compared to 39.03 months with a 95% CI of (39.03, NE) for the placebo arm. Statistical significance was not reached in overall survival at the pre-specified interim analysis.
Slovenian: Mediana preživetja v skupini z apalutamidom ni bila dosežena v primerjavi s skupino s placebom, kjer je bila 39,03 meseca (95% IZ: 39,03, NE).
English: Male fertility is likely to be impaired by treatment with apalutamide based on findings in repeat-dose toxicology studies which were consistent with the pharmacological activity of apalutamide.
Slovenian: Glede na rezultate študij toksičnosti pri ponavljajočih odmerkih zdravljenje z apalutamidom z veliko verjetnostjo zmanjša plodnost pri moških, kar je skladno s farmakološkim delovanjem apalutamida.
English: OTHER Fold over to close
Slovenian: Zapognite in zaprite.
English: Erleada contains sodium
Slovenian: Zdravilo Erleada vsebuje natrij
English: Mild or moderate inhibitors of CYP2C8 are not expected to affect the exposure of apalutamide.
Slovenian: Pri uporabi blagih oziroma zmernih zaviralcev CYP2C8 ni pričakovati vpliva na izpostavljenost apalutamidu.
English: Drug transporters
Slovenian: Prenašalci zdravil